Drugs / JKN2501
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07207291 | Aug 2025 → Mar 2026 overdue | bacterial infectious disease, infectious peritonitis, respiratory tract infectious disorder, urinary tract infection | Joincare Pharmaceutical Group Industry Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JKN2501 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07207291 ↗ |
| Route | Intravenous | “Administration: Intravenous (IV) infusion.” NCT07207291 ↗ |